Combination therapy for advanced solid tumors with neuroendocrine features
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of three drugs (surufatinib, serplulimab, and standard chemotherapy) as a first treatment for advanced solid tumors that have neuroendocrine differentiation. The goal is to see if this combination helps control the cancer better than standard therapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer of the esophagus, bile duct, pancreas, or stomach that cannot be removed with surgery.
- Your tumor shows signs of neuroendocrine differentiation (has certain proteins like CgA or Syn), even though it is not a typical neuroendocrine tumor.
- You have not had any systemic treatment (like chemotherapy) for your cancer before.
- You are physically active (able to do light work or be up and about).
- You do not have high blood pressure that is not controlled by medication.
- You do not have active bleeding or a high risk of bleeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a combination of surufatinib and immunotherapy (camrelizumab, plus an “AS” medicine) can slow or shrink advanced pancreatic cancer that has spread. It is for people starting treatment for advanced disease for the first time and may help those who have measurable tumors and meet safety test limits.
This trial tests a new combination of drugs for people with bile duct cancer that cannot be removed by surgery or has spread. The treatment combines a targeted drug (surufatinib) with immunotherapy and chemotherapy to try to shrink tumors and improve outcomes.
This trial tests the drug surufatinib in people with advanced neuroendocrine tumors. It is a real-world study, meaning it looks at how the drug works in everyday practice, and may help control tumor growth.
This study tests a combination of two medications (surufatinib and serplulimab) for advanced solid tumors that have stopped responding to standard treatment and show special neuroendocrine markers. The goal is to see if this combination can shrink tumors and help you live longer.
This trial tests a combination of two targeted therapies (surufatinib and serplulimab) plus standard chemotherapy (platinum and etoposide) for people with a rare, aggressive type of cancer called neuroendocrine carcinoma that started outside the lung. The goal is to see if this new combination works better than chemotherapy alone.
This trial tests a combination of two oral and intravenous drugs – surufatinib and tislelizumab – for people with advanced lung cancer that shows certain hormone-like cell traits. The goal is to see if this pair can shrink or slow the cancer better than current treatments.
Hear when a new ESCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.